can you take ivermectin with semaglutide As GLP-1 drugs continue to

Funding The work was supported by the grants of: The National Natural Science Foundation of China (No

Under the deal, Novo Nordisk has secured the exclusive worldwide license to use Ascendis TransCon technology platform to develop, produce, and sell products for metabolic diseases, including obesity and Type 2 diabetes with the primary goal being to develop a monthly GLP-1

It means there is no established data on how these peptides behave in human pharmacokinetics, what adverse events occur at what frequencies, or what drug interactions are possible

Get the Brighter Side of News' newsletter .

If you want to learn more about how GLP-1 treatment fits into a broader plan, this article on how GLP-1 actually works for weight loss is a good place to continue